Publique un comentario 
Sobre los marcadores bioquímicos del daño arterioesclerótico
Texto completo:
PDFResumen
mismos sostienen con factores promotores del daño ateroesclerótico. Investigaciones ulteriores se deben orientar a establecer la capacidad del biomarcador de responder ante la terapéutica instalada, y si este cambio se puede trasladar hacia una reducción del riesgo vascular.
Palabras clave
Referencias
Santulli G. Epidemiology of cardiovascular disease in the 21st century: Updated numbers and updated facts. J Cardiovasc Dis 2013;1:1-2.
Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. World Health Organization. Geneva: 2011. Disponible
en: http://www.who.int/entity/cardiovascular_diseases/publications/atlas_cvd/en/index.html. Fecha de última visita: 12 de Septiembre del 2016.
Banack HR, Harper S, Kaufman JS. Coronary heart disease risk factors and mortality. JAMA 2012;307:1137-8.
Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: A review of global methodologies of
mortality measurement. Circulation 2013;127:749-56.
Reddy KS. Cardiovascular diseases in the developing countries: Dimensions, determinants, dynamics and directions for public health action. Public Health Nutrition 2002;5(1A):231-7.
Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J 2004;148:7-15.
Bloom D, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom L, Fathima S; et al. The global economic burden of
noncommunicable diseases. Program on the Global Demography of Aging. Geneva: 2012. Disponible en:
http://econpapers.repec.org/paper/gdmwpaper/8712.htm. Fecha de última visita: 12 de Septiembre del 2016.
Tarride JE, Lim M, DesMeules M, Luo W, Burke N, O’Reilly D; et al. A review of the cost of cardiovascular disease. Can J Cardiol 2009;25(6):E195-E202.
Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income
and middle-income countries. The Lancet 2007;370(9603):1929-38.
World Health Organization. Prevention of cardiovascular disease: Guidelines for assessment and management of
cardiovascular risk. Geneva: 2007. Disponible en:
http://www.who.int/cardiovascular_diseases/publications/Prevention_of_Cardiovascular_Disease/en/. Fecha de última visita: 12 de Septiembre del 2016.
Smith SC, Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O; et al. Principles for national and regional
guidelines on cardiovascular disease prevention. Circulation 2004;109:3112-21.
Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality
reported in 56 population-based studies: A systematic review. The Lancet Neurology 2009;8:355-69.
Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: Incidence, prevalence, mortality, and risk factors. Neurologic Clinics 2008;26:871-95.
Mascarenhas JV, Albayati MA, Shearman CP, Jude EB. Peripheral arterial disease. Endocrinol Metab Clin North Am 2014;43:149-66.
Leng GC, Lee AJ, Fowkes FG; et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172-11.
Magnussen CG, Niinikoski H, Juonala M, Kivimäki M, Rönnemaa T, Viikari JS; et al. When and how to start
prevention of atherosclerosis? Lessons from the cardiovascular risk in the Young Finns Study and the Special
Turku Coronary Risk Factor Intervention Project. Pediatr Nephrol 2012;27:1441-52.
Bobryshev YV, Karagodin VP, Kovalevskaya ZI, Myasoedova VA, Shapyrina EV, Salyamov VI; et al. The number of cells and the cell proliferation in intima of various human arteries. Cell Tissue Biol 2012;6:29-39.
Hansson GK, Robertson AKL, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol Mech
Dis 2006;1:297-329.
Robertson AKL, Hansson GK. T cells in atherogenesis. Arteriosclerosis Thrombosis Vascular Biol 2006;26:2421-32.
Walton KW, Williamson N. Histological and immunofluorescent studies on the evolution of the human atheromatous plaque. J Atherosclerosis Res 1968;8:599-624.
Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circulation 2013;22:399-411.
Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circulation Res 2014;114:1852-66.
Thim T, Hagensen MK, Bentzon JF, Falk E. From vulnerable plaque to atherothrombosis. J Int Med 2008;263:506-16.
Demer LL, Tintut Y. Vascular calcification. Circulation 2008;117:2938-48.
Demer LL, Watson KE, Boström K. Mechanism of calcification in atherosclerosis. Trends Cardiov Med 1994;4:45-9.
Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary
atherosclerosis progressed? Arteriosclerosis Thrombosis Vasc Biol 2014;34:724-36.
Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN; et al. Atherosclerotic plaque progression and
vulnerability to rupture. Arteriosclerosis Thrombosis Vasc Biol 2005;25:2054-61.
Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 2003;41(4 Suppl):S15-S22.
Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier. J Am Coll Cardiol 1994;23:809-13.
Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-1478.
Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in
men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-82.
Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Effect of risk factors on the mechanism of acute
thrombosis and sudden coronary death in women. Circulation 1998;97:2110-6.
Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arteriosclerosis Thromb Vasc Biol 2010;30:1282-92.
Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: Part I: Evolving
concepts. J Am Coll Cardiol 2005;46:937-54.
Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47(8 Suppl):C13-C18.
Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: The pathology of unstable coronary lesions. J
Intervent Cardiol 2002;15:439-46.
Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E; et al. Multiple atherosclerotic plaque rupture
in acute coronary syndrome. Circulation 2002;106:804-8.
Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J; et al. From vulnerable plaque to vulnerable
patient. Circulation 2003;108:1664-72.
Egred M, Viswanathan G, Davis GK. Myocardial infarction in young adults. Postgrad Med J 2005;81:741-5.
Osula S, Bell GM, Hornung RS. Acute myocardial infarction in young adults: Causes and management. Postgrad Med J 2002;78:27-30.
Kanitz MG, Giovannucci SJ, Jones JS, Mott M. Myocardial infarction in young adults: Risk factors and clinical features.
J Emerg Med 1996;14:139-45.
Min JK, Shaw LJ, Devereux RB, Okin PM, Weinsaft JW, Russo DJ; et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol 2007;50:1161-70.
Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary
angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary
artery disease? Circulation 1988;78:1157-66.
Catalano C, Fraioli F, Laghi A, Napoli A, Bezzi M, Pediconi F; et al. Infrarenal aortic and lower-extremity arterial
disease: Diagnostic performance of multi-detector row CT angiography. Radiology 2004;231:555-63.
Meaney TF, Weinstein MA, Buonocore E, Pavlicek W, Borkowski GP, Gallagher JH; et al. Digital subtraction angiography of the human cardiovascular system. Am
J Roentgenol 1980;135:1153-60.
Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel E; et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med 2001;345:1863-9.
Schroeder S, Kopp AF, Baumbach A, Meisner C, Kuettner A, Georg C; et al. Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. J Am Coll Cardiol 2001;37:1430-5.
Callister TQ, Cooil B, Raya SP, Lippolis NJ, Russo DJ, Raggi P. Coronary artery disease: Improved reproducibility of
calcium scoring with an electron-beam CT volumetric method. Radiology 1998;208:807-14.
Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs Jr DR; et al. Calcified coronary artery plaque
measurement with cardiac CT in population-based studies: Standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology
;234:35-43.
Mautner GC, Mautner SL, Froehlich J, Feuerstein IM, Proschan MA, Roberts WC, Doppman JL. Coronary artery
calcification: Assessment with electron beam CT and histomorphometric correlation. Radiology 1994;192:619-23.
de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004;109(23 Suppl 1):S11-S33.
Howard G, Chambless LE, Baker WH, Ricotta JJ, Jones AM, O'Leary D; et al. A multicenter validation study of
Doppler ultrasound versus angiography. J Stroke Cerebrovasc Dis 1991;1:166-73.
Grant EG, Benson CB, Moneta GL, Alexandrov AV, Baker JD, Bluth EI; et al. Carotid artery stenosis: Gray-scale and Doppler US diagnosis. A Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003;229:340-6.
AbuRahma AF, Kyer PD, Robinson PA, Hannay RS. The correlation of ultrasonic carotid plaque morphology and carotid plaque hemorrhage: Clinical implications. Surgery 1998;124:721-8.
Tegos TJ, Sohail M, Sabetai MM, Robless P, Akbar N, Pare G; et al. Echomorphologic and histopathologic characteristics of unstable carotid plaques. Am J Neuroradiology 2000;21:1937-44.
Sigel B. A brief history of Doppler ultrasound in the diagnosis of peripheral vascular disease. Ultrasound Med Biol 1998;24:169-76.
Coll B, Betriu A, Feinstein SB, Valdivielso JM, Zamorano JL, Fernández E. The role of carotid ultrasound in assessing carotid atherosclerosis in individuals at low-to-intermediate cardiovascular risk. Rev Española Cardiol 2013;66:929-34.
Postley JE, Luo Y, Wong ND, Gardin JM. Identification by ultrasound evaluation of the carotid and femoral arteries of high-risk subjects missed by three validated cardiovascular disease risk algorithms. Am J Cardiol 2015;116:1617-23.
Núñez F, Martínez-Costa C, Sánchez-Zahonero J, Morata J, Chorro FJ, Brines J. Carotid artery stiffness as an early marker of vascular lesions in children and adolescents with cardiovascular risk factors. Rev Española Cardiol 2010;63:1253-60.
Johnsen SH, Mathiesen EB. Carotid plaque compared with intima-media thickness as a predictor of coronary and
cerebrovascular disease. Cur Cardiol Reports 2009;11:21-7.
Honda O, Sugiyama S, Kugiyama K, Fukushima H, Nakamura S, Koide S; et al. Echolucent carotid plaques predict future coronary events in patients with coronary artery disease. J Am Coll Cardiol 2004;43:1177-84.
Grønholdt MLM, Nordestgaard BG, Schroeder TV, Vorstrup S, Sillesen H. Ultrasonic echolucent carotid plaques predict future strokes. Circulation 2001;104:68-73.
Durga J, Verhoef P, Bots ML, Schouten E. Homocysteine and carotid intimamedia thickness: A critical appraisal of
the evidence. Atherosclerosis 2004;176:1-19.
Folsom AR, Pankow JS, Williams RR, Evans GW, Province MA, Eckfeldt JH. Fibrinogen, plasminogen activator
inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thrombosis Haemostasis 1998;79:400-4.
Sosef MN, Bosch JG, Van Oostayen J, Visser T, Reiber JH, Rosendaal FR. Relation of plasma coagulation factor
VII and fibrinogen to carotid artery intima-media thickness. Thrombosis Haemostasis 1994;72:250-4.
Cao JJ, Arnold AM, Manolio TA, Polak JF, Psaty BM, Hirsch CH; et al. Association of carotid artery intimamedia
thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality. Circulation 2007;116:32-8.
Crouse JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH; et al.; for the METEOR Study Group.
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA 2007;297:1344-53.
Smilde TJ, van Wissen S, Awollersheim H, Trip MD, Kastelein J, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): A prospective,
randomised, double-blind trial. The Lancet 2001;357(9256):577-81.
Tousoulis D, Kampoli AM, Stefanadi E, Antoniades C, Siasos G, Papavassiliou AG, Stefanadis C. New biochemical markers in acute coronary syndromes. Cur Med Chem 2008;15:1288-96.
Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004;25:1187-96.
Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the pioneer study. J Am Coll Cardiol 2005;45:1925-31.
Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: A historical perspective. The
Lancet 2014;383(9921):999-1008.
Castelli WJ, Garrison RJ, Wilson PWF, Abbot RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8.
Goodman DS, Hulley SB, Clark LT, Davis CE, Fuster V, La Rosa JC; et al; for the Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Int Med 1988;148:36-69.
Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
Rader DJ. Spotlight on HDL biology: New insights in metabolism, function, and translation. Cardiovasc Res 2014;103:337-40.
Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nature Rev Cardiol 2011;8:222-32.
Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and antiatherogenic properties of HDL. J Lipid
Res 2009;50(Suppl):S195-S200.
Goldstein LJ, Brown SM. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977;46:897-930.
Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem
Soc Trans 2003;31(Pt 5):1066. Disponible en:
https://www.ncbi.nlm.nih.gov/pubmed/14505481. Fecha de última visita: 3 de Octubre del 2016.
Ridker PM. LDL cholesterol: Controversies and future therapeutic directions. The Lancet 2014;384(9943):607-17.
Rader DJ, Hovingh GK. HDL and cardiovascular disease. The Lancet 2014;384(9943):618-25.
Zweig MH, Broste SK, Reinhart RA. ROC curve analysis: An example showing the relationships among serum lipid and apolipoprotein concentrations in identifying patients with coronary artery disease. Clin Chem 1992;38:1425-8.
Superko HR, King S. Lipid management to reduce cardiovascular risk: A new strategy is required. Circulation 2008;117:560-8.
Baigent C, Keech A, Kearney PM, Blackwell L. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet 2005;366(9493):1267-74.
Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood
cholesterol based on an individual's absolute cardiovascular risk. The Lancet 2005;365(9457):434-41.
Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials. JAMA 1997;278:313-21.
Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF; et al. Lipoprotein (a) as a cardiovascular risk factor: Current status. Eur Heart J 2010;31:2844-53.
Erqou S, Kaptoge S, Perry PL, di Angelantonio E, Thompson A, White IR; et al.; for the Emerging Risk Factors
Collaboration. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.
Lehner R, Kuksis A. Biosynthesis of triacylglycerols. Prog Lipid Res 1996;35:169-201.
Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(4 Suppl):7B-12B.
Hernández Castro JL. Sobre la asociación entre los lípidos sanguíneos y la presencia de ateroesclerosis regional. RCAN Rev Cubana Aliment Nutr 2014;24:17-34.
García Sánchez N, León Álvarez JL. Sobre el comportamiento de biomarcadores de la arteriosclerosis en la hipertensión arterial. RCAN Rev Cubana Aliment Nutr 2016:26:252-74.
García Sánchez N, León Álvarez JL. Biomarcadores de la arteriosclerosis como predictores del riesgo cardiovascular en la hipertensión arterial no complicada. RCAN Rev Cubana Aliment Nutr 2016;26:275-83.
Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-90.
Tillett WS, Francis T. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J Exp Med 1930;52:561-71.
Szalai AJ. The biological functions of Creactive protein. Vasc Pharmacol 2002;39:105-7.
Li JJ, Fang CH. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Medical Hypotheses 2004;62:499-506.
Thorand B, Löwel H, Schneider A, Kolb H, Meisinger C, Fröhlich M, Koenig W. C-reactive protein as a predictor for incident Diabetes mellitus among middle-aged men: Results from the MONICA Augsburg cohort study, 1984-1998. Arch Int Med 2003;163:93-9.
Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006;61:23-8.
Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing
hypertension. JAMA 2003;290:2945-51.
Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of plasma high-sensitivity C-reactive
protein to traditional cardiovascular risk factors. Atherosclerosis 2003;167:73-9.
Florez H, Castillo-Florez S, Mendez A, Casanova-Romero P, Larreal-Urdaneta C, Lee D, Goldberg R. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res Clin Pract 2006;71:92-100.
Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O; et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the Metabolic syndrome. Int J Obes 2004;28:674-9.
Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
Strandberg TE, Vanbanen H, Tikkanen MJ. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 2000;32:579-83.
Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003;289:1799-1804.
Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment
of global cardiovascular risk in women: The Reynolds Risk Score. JAMA 2007;297:611-9.
Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC. C-reactive protein: Relation
to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-90.
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-25.
Kaski JC, Fernández-Bergés DJ, Consuegra-Sánchez L, Fernández JMC, García-Moll X, Mostaza JM; et al. A comparative study of biomarkers for risk prediction in acute coronary syndrome- Results of the SIESTA (Systemic
Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. Atherosclerosis 2010;212:636-43.
Fernández-Miranda C, Sala XP; para el Grupo Multidisciplinario para el Estudio del Riesgo Cardiovascular. Nuevas perspectivas en la medición del
riesgo cardiovascular: Exploraciones para detectar la aterosclerosis subclínica y marcadores de inflamación. Medicina Clínica [Barcelona] 2007;128:344-51.
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH; et al. C-reactive protein levels and outcomes
after statin therapy. N Engl J Med 2005;352:20-8.
Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating
Rosuvastatin (JUPITER)- Can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006;97:33-41.
Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y; et al. Brain natriuretic peptide as a novel cardiac
hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-9.
McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG; et al. B-type natriuretic peptide
and clinical judgment in emergency diagnosis of heart failure. Circulation 2002;106:416-22.
de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. The Lancet,
;362(9380):316-22.
Goetze JP. Biochemistry of pro-Btype natriuretic peptide-derived peptides: The endocrine heart revisited. Clin Chem 2004;50:1503-10.
James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P; et al. N-terminal pro-brain natriuretic
peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in
patients with unstable coronary artery disease. Circulation 2003;108:275-81.
Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM; et al. Brain natriuretic
peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in
experimental heart failure. Circulation 2004;109:1680-5.
Currie MG, Geller DM, Cole BR, Boylan JG, YuSheng WU, Holmberg SW, Needleman P. Bioactive cardiac substances: Potent vasorelaxant activity in mammalian atria. Science 1983;221(4605):71-3.
Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-9.
Danesh J, Lewington S, Thompson SG, Lowe G, Collins R, Kostis J; et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA 2005;294:1799-1809.
Meade TW, Vickers MV, Thompson SG, Seghatchian MJ. The effect of physiological levels of fibrinogen on
platelet aggregation. Thrombosis Res 1985;38:527-34.
Eber B, Schumacher M. Fibrinogen: Its role in the hemostatic regulation in atherosclerosis. Sem Thrombosis
Hemostasis 1993;19:104-7.
Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y; et al. Plasma fibrinogen levels as an independent
indicator of severity of coronary atherosclerosis. Atherosclerosis 1989;77:209-13.
Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney
Dis 2000;35(4 Suppl):S117-S131.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the Atherosclerosis Risk in Communities Study. J Am Soc
Nephrol 2005;16:529-38.
Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M; et al. Chronic kidney disease and mortality
risk: A systematic review. J Am Soc Nephrol 2006;17:2034-47.
Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL; et al. Chronic kidney disease as a risk factor
for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc
Nephrol 2004;15:1307-15.
Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B; et al. Albuminuria and risk of cardiovascular
events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
Hillege HL, Janssen WMT, Bak AAA, Diercks GFH, Grobbee DE, Crijns HJGM; et al. Microalbuminuria is
common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular
risk factors and cardiovascular morbidity. J Int Med 2001;249:519-26.
Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR; et al.; for the Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-9.
Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE; et al. Progression of chronic kidney disease:
The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level metaanalysis. Ann Int Med 2003;139:244-52.
Seronie-Vivien S, Delanaye P, Pieroni L, Mariat C, Froissart M, Cristol JP. Cystatin C: Current position and
future prospects. Clin Chem Lab Med 2008;46:1664-86.
Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004;41:467-550.
Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009;55:1932-43.
Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem 2005;51:321-7.
Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-breen C; et al. Cystatin C and prognosis for
cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Int Med 2006;145:237-46.
Singh D, Whooley MA, Ix JH, Ali S, Shlipak MG. Association of cystatin C and estimated GFR with inflammatory biomarkers: The Heart and Soul Study.
Nephrol Dial Transplant 2007;22:1087-92.
Arimoto T, Takeishi Y, Niizeki T, Takabatake N, Okuyama H, Fukui A; et al. Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J Cardiac Fail 2005;11:595-601.
Eriksson P, Deguchi H, Samnegård A, Lundman P, Boquist S, Tornvall P; et al. Human evidence that the cystatin C gene is implicated in focal progression of
coronary artery disease. Arteriosclerosis Thromb Vasc Biol 2004;24:551-7.
Randers E, Kornerup K, Erlandsen EJ, Hasling C, Danielsen H. Cystatin C levels in sera of patients with acute
infectious diseases with high C-reactive protein levels. Scand J Clin Lab Invest 2001;61:333-5.
Lassus J, Harjola VP, Sund R, Siirilä-Waris K, Melin J, Peuhkurinen K; et al. Prognostic value of cystatin C in acute
heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007;28:1841-7.
Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C: A replacement for creatinine as a biochemical marker of GFR. Kidney Int
;47(Suppl):S20-S27.
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T; et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-9.
Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J; et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395-406.
Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: New insights into old concepts. Clin Chem 1992;38:1933-53.
Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate
glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Int Med 2004;141:929-37.
Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med 1988;39:465-90.
Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate
glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Int Med 2004;141:929-37.
Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease. Stroke 1997;28:557-63.
Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Int Med 2001;161:886-91.
Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O; et al. Early detection of acute renal
failure by serum cystatin C. Kidney Int 2004;66:1115-22.
Ebashi S, Wakabayashi T, Ebashi F. Troponin and its components. J Biochem 1971;69:441-5.
Mazzone A, De Servi S, Mazzucchelli I, Bossi I, Ottini E, Vezzoli M; et al. Increased concentrations of inflammatory mediators in unstable angina: Correlation with serum troponin T. Heart 2001;85:571-5.
Löwbeer C, Stenvinkel P, Pecoits‐Filho R, Heimbürger O, Lindholm B, Gustafsson SA, Seeberger A. Elevated
cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. J Int Med 2003;253:153-60.
Adams JR, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS. Cardiac troponin I. A
marker with high specificity for cardiac injury. Circulation 1993;88:101-6.
Kemp M, Donovan J, Higham H, Hooper J. Biochemical markers of myocardial injury. Brit J Anaesthesia 2004;93:63-73.
Mair J, Morandell D, Genser N, Lechleitner P, Dienstl F, Puschendorf B. Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. Clin Chem 1995;41:1266-72.
Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001;56:1-22.
Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001;44:129-46.
Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free
Radical Biol Med 1991;10:339-52.
Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J; et al. Advanced
oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13.
Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin
assay. N Engl J Med 1984;310:341-6.
Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and
hemoglobin AIc in Diabetes mellitus. N Engl J Med 1976;295:417-20.
Gonen B, Rochman H, Rubenstein A, Tanega S, Horwitz D. Haemoglobin A1: An indicator of the metabolic control of diabetic patients. The Lancet 1977;310(8041):734-7.
Gabbay KH, Hasty K, Breslow JL, Ellison RC, Bunn HF, Gallop PM. Glycosylated hemoglobins and long-term
blood glucose control in Diabetes mellitus. J Clin Endocrinol Metab 1977;44:859-64.
Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Cur Op Lipidol 2006;17:637-43.
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: Glycosylated hemoglobin and cardiovascular disease
in Diabetes mellitus. Ann Int Med 2004;141:421-31.
Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J; et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-11.
Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust Diabetes
therapy improves glycosylated hemoglobin: A pilot study. Diabetes Res Clin Pract 1999;46:183-90.
Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocrine J
;57:751-62.
Yoshiuchi K, Matsuhisa M, Katakami N, Nakatani Y, Sakamoto K, Matsuoka T; et al. Glycated albumin is a
better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocrine J 2008;55:503-7.
Kim KJ, Lee BW. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diab Metab J 2012;36:98-107.
Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC. Serum glycated albumin predicts the progression of carotid arterial atherosclerosis. Atherosclerosis 2012;225:450-5.
Pu LJ, Lu L, Shen WF, Zhang Q, Zhang RY, Zhang JS; et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circulation J 2007;71:1067-73.
Enlaces refback
- No hay ningún enlace refback.
La revista está: Certificada por el CITMA
La revista es de acceso abierto y gratuito.